Jun 18 2012
KineMed, Inc. (www.kinemed.com) announced today a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) (LSE: GSK, NYSE: GSK) that will apply KineMed's proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize and validate novel biomarkers that would enable more informed and timely decision-making in clinical trials of compounds for muscle wasting, fibrosis and metabolic diseases.
“We are delighted to announce this collaboration. The marriage of KineMed's insights into biology with GSK's clinical portfolio marks the start of an exceptional initiative to advance innovative evidence-based medicines.”
David Fineman, President & CEO of KineMed, said, "We are delighted to announce this collaboration. The marriage of KineMed's insights into biology with GSK's clinical portfolio marks the start of an exceptional initiative to advance innovative evidence-based medicines."
Marc Hellerstein, M.D., Ph.D., Chief of the Scientific Advisory Board of KineMed, stated: "Our shared goal with GSK is to identify causal pathways and kinetic signatures that can better inform drug development decisions. The missing links in developing drugs to treat muscle wasting, fibrosis and metabolic diseases have been reliable biomarkers that measure the degree to which we are having therapeutic impact on their underlying disease processes. KineMed's technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them."
Source KineMed, Inc.
Progress in early detection and screening methods for pancreatic cancer